Biochemical Importance and Kinetic Studies of Placental Alkaline Phosphatase Isoenzyme as a Predictor Marker of Primary Malignancies

Noor Kareem Aead[1], Fadhil Jawad Al-Tuma[2], Rana Majeed Hameed[3], Riyadh Abd-Alrasool Hnewa[4]

[1]MSC Student, [2]Prof. [3]Asst Prof., Biochemistry Department/ College of Medicine/ University of Kerbala;
[4]Physician, Chemical Pathologist/ AL-Hussain Teaching Hospital/ Kerbala

Abstract

Lung cancer is the main cause of cancer-related death worldwide and conventional diagnostic strategies must be improved. developments of a simple method or techniques which would enable researchers to identify and validate the early screening biomarker of lung cancer patients.

The aims of this article were to review the background documents on the state of the art of the scientific literature in studies that used Placental alkaline phosphatase in the diagnostic of lung cancer also to suggest areas where further research is needed, either to deal with gaps in the knowledge related to employ the heat stability of Placental alkaline phosphatase or assessment the quantitation methods of the isoenzyme.

Keywords: *Biochemical; Kinetic Studies; Placental Alkaline Phosphatase Isoenzyme; Predictor Marker ; Primary Malignancies*

Introduction

Cancer is a wide term, It can be labeled as an illness that outcome once cellular changes cause the uncontrolled growth and division. Most of the body's cells have particular functions and fixed lifetimes. Cancerous cells lack the mechanisms that train them to stop dividing and to die [(1)].

Lung cancer is a malignant lung tumor considered by uncontrolled cell growth in lung tissues [(2)]. It could be classified according to histological type [(3)]. This classification is important for determining both the management and predicting outcomes of the disease. two broad classes are distinguished: non-small cell lung cancer and small-cell lung carcinoma [(4)].

Non-small-cell lung carcinoma(NSCLC)

The three main subtypes of Non-small cell lung carcinoma are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [(5)] .Nearly 40% of lung cancers are adenocarcinoma, which usually comes from peripheral lung tissue [(2)].Although most cases of adenocarcinoma are associated with smoking, adenocarcinoma is also the most-common form of lung cancer among people who have smoked fewer than 100 cigarettes in their lifetimes and ex-smokers with a modest smoking history [(6)].

Squamous-cell carcinoma

It causes about 30% of lung cancers. They typically occur close to large airways. Nearly 9% of lung cancers are large-cell carcinoma. These are so named because the cancer cells are large, with excess cytoplasm, large nuclei, and conspicuous nucleoli **(2)**

Small-cell lung carcinoma (SCLC)

In SCLC, the cells contain dense neurosecretory granules , 60-70%have extensive disease , most cases arise in the larger airways (primary and secondary bronchi) [(7)] **.**

Lung cancer diagnostic techniques

· **Imaging Tests**; Imaging tests create pictures of the inside of the body by using X-rays, magnetic fields, sound waves, or radioactive particles [(8)] .

· **chest X-ray** : is a type of high-energy radiation that goes through the body and onto film to produce a picture. A chest X-ray produces pictures of the organs in the chest, including the lungs, airways, heart, and blood vessels [9]

· **Computed tomography(CT or CAT scan);** uses a computer linked to an X-ray machine to make detailed pictures of the inside of the body. Three-dimensional (3D) views of the organs and tissues can be created. A CT scan can provide specific information about the size, shape, and position of masses or nodules in the lung [10]**.**

· **Magnetic resonance imaging (MRI)**: is used in lung cancer to find out whether the cancer has spread to the brain or spinal cord**.** MRI scans provide detailed pictures of areas inside the body by using radio waves and strong magnets. The energy from the radio waves is absorbed and then released in a pattern that a computer translates into images. A contrast dye is usually injected intravenously prior to the MRI to make clearer images [11]**.**

· **Positron emission tomography (PET) scan:** It done by using radioactive sugar which is given intravenously to the patient. Because cancer cells grow rapidly, they absorb more of the radioactive sugar than healthy cells. one hour after, patient would placed on a table in the PET scanner for approximately 30 minutes while a special camera creates a picture of the areas in the body that absorbed the radioactive sugar [12].

· **Biopsies :** Tissue biopsies are tests in which small amounts of tissue are removed for examination to find out if a person has lung cancer [13].

Biomarkers of lung cancer

Due to its high incidence rate and poor prognosis, lung cancer, as the leading cause of cancer-related mortality worldwide [14]**.** It has become a serious and growing disease burden throughout the world. Therefore, scientific researchers aimed to develop a more reliable diagnostic modality to identify early-stage lung cancer is an urgent priority. Tumor markers measured in serum could be a tool for identifying patients with high risk of recurrent disease. The usefulness of different tumor markers in lung cancer diagnostics, prognostics and disease monitoring has been studied intensely, but often with conflicting results. Many biochemical markers were investigated their prognostic role in lung cancer such as Carcinoembryonic antigen (CEA), Cancer antigen (CA 125), Carbohydrate antigen (CA 19–9), Human epididymis protein 4 (HE4) and Neuron-specific enolase (NSE [15].

Carcinoembryonic antigen (CEA)

Is a glycoprotein produced during embryonal and fetal development. In adults it is produced in low amounts by the gastrointestinal tract, the pancreas and liver. Elevated CEA in cancer is hypothesized to be caused by a loss of repression of CEA-encoding genes [16]. In lung cancer, the use of CEA has been reported for differential diagnosis of malignant lung tumor. Several studies have suggested CEA as a prognostic marker in non-small cell lung cancer (NSCLC) but results are conflicting [17].

Cancer antigen 125 (CA-125)

Is a glycoprotein produced in fetal tissue, also in mesothelial cells in adults. It has been extensively studied as a tumor marker for screening and management of ovarian cancer [18].It has reported that CA 125 as a marker for worse prognosis in lung cancer. [19]**.**

Carbohydrate antigen 19–9(CA 19-9):

Marker used in management of pancreatic tumors. It has also been studied in lung cancer. CA 19–9 in bronchoalveolar lavage fluid, has been identified as a potential diagnostic marker of lung cancer in a study by Ghosh et al. [20]

Human epididymis protein 4(HE4)

Is a protein expressed in tissues such as genital tract and respiratory epithelium. Overexpression of the protein has been detected in ovarian cancer but also in lung adenocarcinoma and other cancers. It has been suggested as a tumor marker useful in diagnosing ovarian cancer, especially in premenopausal women **.** In lung cancer it has been suggested as a potential diagnostic [21] and prognostic marker [22].

Neuron-specific enolase (NSE)

Is a glycolytic neurospecific isoenzyme found in tumors of neural and neuroectodermal origin such as

small cell lung cancer (SCLC) and neuroblastoma. NSE is also found in erythrocytes, plasma cells and platelets [23]. In patients with NSCLC, NSE has been suggested as a prognostic marker and some studies have presented an association between increased NSE and shorter survival in *EGFR*-mutated NSCLC treated with tyrosine kinase inhibitors (TKI´s) [24]

ALKALINE PHOSPHATASE

Alkaline phosphatase (ALP) is a membrane-bound metalloenzymes which have an active site facing the extracellular space [25].They hydrolyze phosphate monoesters and are involved in several cellular events including protein phosphorylation, cell growth, and apoptosis. Based on their tissue distribution, Alkaline phosphatase is classified into: tissue specific alkaline phosphatase including placental ALP (PALP), and intestinal ALP(IALP) and tissue non-specific alkaline phosphatase (TNAP) including liver ALP(LALP) and bone ALP(BALP) [26].

Alkaline Phosphatase Isoenzymes and their Clinical Significant

Summary of the alkaline phosphatase isoforms and their clinical significance were listed in the Table (1).

Some of the tumor-associated enzymes are attributed to the placental-like alkaline phosphatase, they are structurally related to the term placental alkaline phosphatase, For this reason the placental isoenzyme has attracted much interest [27]. TNAP is mainly expressed in liver and bone but is also found in circulating leukocytes and colon and its expression within the intestine is increased during inflammation [28]. The function of bone alp believed to play a role in bone matrix mineralization [29]. intestinal ALP is expressed and secreted by intestinal epithelial cells and remains active within the mucosal membrane as well as the intestinal lumen.

Table 1: List of alkaline phosphatase isoforms and their clinical significance

Isoform	Location	Function
Tissue non-specific alkaline phosphatase (TNALP)	Liver Bone	Un known Genetic absence has been linked to hypophosphatemia
Intestinal alkaline phosphatase (IALP)	Intestinal Epithelial Cells	Detoxification of Bacterial Endotoxin. Dephosphorylation of Tri and Di phosphorylated nucleotide. Regulation of the Intestinal Microbiome. Regulation of Intestinal Lipid Absorption.
Placental alkaline phosphase (PALP)	Placenta	Tumor marker for Seminomas and Germ Cell Neoplasms Detoxification of Bacterial Endotoxin

Detection and Quantitation techniques of ALP and their Isoenzymes

1. Stability of denaturation to heat

Liver, bone and intestinal ALPs are rapidly inactivated at temperature >65 °C. In contrast, placental ALP is remarkably thermostable. They may be heated at 65 °C for an hour or more without loss of activity [30].

2. Immunological Techniques

The quantitative measurements of placental and intestinal ALP might be performed using polyclonal or monoclonal antisera. PLAP and intestinal alkaline phosphatase share some antigenic determinants and a cross-reactivity is observed with unabsorbed antisera against PLAP and intestinal ALP. However, monospecific antisera for each form of the enzyme can be prepared by absorption with purified Placental ALP or intestinal ALP [31].

3. Electrophoresis

In gel electrophoresis, isoenzyme fragments are drawn through a thick gel by an electric charge. Each isoenzyme has a distinct charge of its own because of its unique amino acid sequence. This enables gel electrophoresis to separate the fragments into bands for identification. The liver ALP moves rapidly toward the anode following bone ALP then intestinal ALP migrates slowly than the bone ALP, whereas the placental ALP appears as a discrete band overlap the diffuse bone fraction [32].

Placental and placental like alkaline phosphatase isoenzymes and lung cancer

Placental alkaline phosphatase (PALP) is polymorphic and heat stable enzyme. It is localized in apical and basal cells of syncytiotrophoblast plasma membrane [33]. It is synthesized from placental syncytiotrophoblast from the twelfth week of pregnancy and is released into the maternal blood. This enzyme when infused into human subjects, has a biological half life of about seven days and large artificially induced changes in serum alkaline phosphatase concentration may persist for several weeks. In early pregnancy Placental ALP activity is low. Measurable levels of Placental ALP appear in maternal serum by the end of first trimester and increases progressively with gestational age and normally peaks at term [34]. It has suggested to be involved in nutrient transport from mother to fetus and also in transport of maternal IgG to the fetus. Also, It has a role in active transport of phosphates, glucose, fatty acids, and absorption of nutrients and uptake mechanism through the plasma membrane [35]. The central core of PLAP, consisting of an extended β-sheet and flanking α-helices. The overall structure of Placental ALP is a dimer and each monomer contains 484 residues, four metal atoms, one phosphate ion, and 603 water molecules. The two monomers are related by a two-fold crystallographic axis [36].

Placental-like placental alkaline phosphatase and placental alkaline phosphate are virtually identical in amino acid sequence (98% homology) and have a highly restricted tissue expression pattern, expressing in placental trophoblasts only. Both share high homology with the intestinal alkaline phosphatas (87% homology), and some homology with the tissue-nonspecific liver/ bone/ ALP (57% homology) [37]

Placental alkaline phosphatase is known to be highly heat stable, its activity being unchanged after 30min at 70°C as found by fishman et al. in nontrophoblastic tumors. PLAP has been reported in the sera of about 20% of patients with various cancers, although some have reported a prevalence as high as 95% [38].

Implications and contribution to the knowledge gap

Most of detection methods of Alkaline phosphatase isoforms have many merits and limitations [39]. Mainly, its consider as a high cost of equipment, low sample processing speed, physically large instruments and larger required sample volumes. Morever, most detection methods suffer from a lack of sensitivity and specificity, especially in the discrimination between placental and intestinal alkaline phosphatase.

Researcher were needing to develop a detection method of placental alkaline phosphatase and make it available test in any simple lab, also to produce inexpensively and simply operate testing. Also, there is a needing for an experimental assessment to the performance of different techniques such as heating methods to measure the Placental alkaline phosphatase

and compared with highly sensitive method (such as ELISA) to demonstrated and confirmed the accuracy and validity of the both methods. That might be encouraged a potential use of Placental alkaline phosphatase isoenzyme as a simple accessible and affordable biomarker for monitoring lung cancer patients. Moreover, using placental alkaline phosphatase to provide baseline information as a diagnostic marker without needing for advanced facilities.

Ethical Clearance: None

Source of Funding: None

Conflict of Interest: None

References

1. TANDEL, Gopal S., Biswas, M., Kakde, O. G., Tiwari, A., Suri, H. S., Suri, H. S., et al. A review on a deep learning perspective in cancer classification. Cancers, 2019, 11.1: 111.
2. Akram, Sheeraz . Artificial Neural Network Based Classification Of Lungs Nodule Using Hybrid Features From Computerized Tomographic Images. Applied Mathematics & Information Sciences, 2015, 9.1: 183.
3. MAXWELL, Obubu, Kayode, A. A., Olusola, Y. O., Joshua, A. I., & Chinedu, O. V. Lung Cancer: A Chronic Disease Epidemiology; Prevalence Study. Asian Journal of Advanced Research and Reports, 2019, 1-7.
4. KALOGIANNIDOU, Katerina; NIKOLAKOPOULOU, Eftychia; & KOMILIS, Dimitrios. Generation and composition of waste from medical histopathology laboratories. Waste Management, 2018, 79: 435-442.
5. Jameson, J. Larry. Harrison's Principles Of Internal Medicine. Mcgraw-Hill Education, 2018.
6. AGULNIK, J., Kasymjanova, G., Pepe, C., Hurry, M., Walton, R. N., Sakr, L., et al. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec. Current Oncology, 2020, 27.5: e459.
7. SMOLLE, Elisabeth; PICHLER, Martin. Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition. Cancers, 2019, 11.2: 204.
8. KANWAL, Madiha; DING, Xiao-Ji; CAO, Yi. Familial risk for lung cancer. Oncology Letters, 2017, 13.2: 535-542.
9. BANSAL, Taranpal; BEESE, Richard. Interpreting a chest X-ray. British Journal of Hospital Medicine, 2019, 80.5: C75-C79.
10. SAADAT, Mahsa., Manshadi, M. K., Mohammadi, M., Zare, M. J., Zarei, M., Kamali, R.,et al. Magnetic particle targeting for diagnosis and therapy of lung cancers. Journal of Controlled Release, 2020.
11. DEKA, Bhabesh; DATTA, Sumit. Compressed Sensing Magnetic Resonance Image Reconstruction Algorithms. Springer Series on Bio-and Neurosystems, 2019.
12. MASON, Erica Ellis. Magnetic particle imaging for intraoperative breast cancer margin assessment and functional brain imaging. 2020. PhD Thesis. Massachusetts Institute of Technology.
13. VAQUERO, Juan José; BACHARACH, Stephen L. Positron Emission Tomography. Cardiac CT, PET & MR, 2019, 1-37.
14. PADMANABHAN, Vijayalakshmi, Steinmetz, H. B., Rizzo, E. J., Erskine, A. J., Fairbank, T. L., de Abreu, F. B., et al. Improving adequacy of small biopsy and fine-needle aspiration specimens for molecular testing by next-generation sequencing in patients with lung cancer: a quality improvement study at Dartmouth-Hitchcock Medical Center. Archives of pathology & laboratory medicine, 2017, 141.3: 402-409.
15. Cheng, Ting-Yuan David. The International Epidemiology Of Lung Cancer: Latest Trends, Disparities, And Tumor Characteristics. Journal Of Thoracic Oncology, 2016, 11.10: 1653-1671.
16. ISAKSSON, Sofi, Jönsson, P., Monsef, N., Brunnström, H., Bendahl, P. O., Jönsson, M.,et al. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PloS one, 2017, 12.10: e0186284.
17. Molina, Rafael, Holdenrieder, S., Auge, J. M., Schalhorn, A., Hatz, R., & Stieber, P. Diagnostic Relevance Of Circulating Biomarkers In Patients With Lung Cancer. Cancer Biomarkers, 2010, 6.3-4: 163-178.
18. Doubeni Ca, Doubeni Ar, Myers Ae. Diagnosis And Management Of Ovarian Cancer. American Family Physician. 2016, 93.11: 937–44.

19. Sölétormos, György, Duffy, M. J., Hassan, S. O. A., Verheijen, R. H., Tholander, B., Bast, R. C., Et Al. Clinical Use Of Cancer Biomarkers In Epithelial Ovarian Cancer: Updated Guidelines From The European Group On Tumor Markers. International Journal Of Gynecologic Cancer, 2016, 26.1.

20. Ghosh, Indranath, Bhattacharjee, D., Das, A. K., Chakrabarti, G., Dasgupta, A., & Dey, S. K. Diagnostic Role Of Tumour Markers Cea, Ca15-3, Ca19-9 And Ca125 In Lung Cancer. Indian Journal Of Clinical Biochemistry, 2013, 28.1: 24-29.

21. Zeng, Qian, Liu, M., Zhou, N., Liu, L., & Song, X. Serum Human Epididymis Protein 4 (He4) May Be A Better Tumor Marker In Early Lung Cancer. Clinica Chimica Acta, 2016, 455: 102-106.

22. Lamy, Pierre-Jean; Plassot, Carine; Pujol, Jean-Louis. Serum He4: An Independent Prognostic Factor In Non-Small Cell Lung Cancer. Plos One, 2015, 10.6: E0128836.

23. Harmsma, Marjan; Schutte, Bert; Ramaekers, Frans Cs. Serum Markers In Small Cell Lung Cancer: Opportunities For Improvement. Biochimica Et Biophysica Acta (Bba)-Reviews On Cancer, 2013, 1836.2: 255-272.

24. Inomata, M., Hayashi, R., Yamamoto, A., Tokui, K., Taka, C., Okazawa, S., et al. Plasma Neuron-Specific Enolase Level As A Prognostic Marker In Patients With Non-Small Cell Lung Cancer Receiving Gefitinib. Molecular And Clinical Oncology, 2015, 3.4: 802-806.

25. Haarhaus, Mathias, Brandenburg, V., Kalantar-Zadeh, K., Stenvinkel, P., & Magnusson, P. Alkaline Phosphatase: A Novel Treatment Target For Cardiovascular Disease In Ckd. Nature Reviews Nephrology, 2017, 13.7: 429.

26. ZAHER, Dana M., El-Gamal, M. I., Omar, H. A., Aljareh, S. N., Al-Shamma, S. A., Ali, A. J., et al. Recent advances with alkaline phosphatase isoenzymes and their inhibitors. Archiv der Pharmazie, 2020, 353.5: e2000011.

27. Lallès, Jean-Paul. Intestinal Alkaline Phosphatase: Novel Functions And Protective Effects. Nutrition Reviews, 2014, 72.2: 82-94.

28. FAWLEY, Jason; & GOURLAY, David M. Intestinal alkaline phosphatase: a summary of its role in clinical disease. journal of surgical research, 2016, 202.1: 225-234.

29. BOWDEN, S. A.; FOSTER, B. L. Alkaline phosphatase replacement therapy for hypophosphatasia in development and practice. In: Therapeutic Enzymes: Function and Clinical Implications. Springer, Singapore, 2019. p. 279-322.

30. BRICHACEK, Allison L.; & BROWN, Candice M. Alkaline phosphatase: a potential biomarker for stroke and implications for treatment. Metabolic brain disease, 2019, 34.1: 3-19.

31. THAN, Gabor N.; BOHN, Hans; & SZABO, Denes G. Advances in Pregnancy-Related Protein Research Functional and Clinical Applications. CRC Press, 2020.

32. CHROMÝ, Vratislav, Vinklárková, B., Šprongl, L., & Bittová, M. The Kjeldahl method as a primary reference procedure for total protein in certified reference materials used in clinical chemistry. I. A review of Kjeldahl methods adopted by laboratory medicine. Critical reviews in analytical chemistry, 2015, 45.2: 106-111.

33. SHEVADE, Sapna Prashant, Arole, V., Paranjape, V. M., & Bharambe, V. K. Histochemistry of placental alkaline phosphatase in preeclampsia. Int J Biomed Adv Res, 2016, 7: 323-8.

34. KUĆ, Sylwia. First trimester screening for maternal and fetal disease: A search for novel biomarkers. 2014. PhD Thesis.

35. HIRSCHMUGL, Birgit, Crozier, S., Matthews, N., Kitzinger, E., Klymiuk, I., Inskip, H. M., & Wadsack, C. Relation of placental alkaline phosphatase expression in human term placenta with maternal and offspring fat mass. International Journal of Obesity, 2018, 42.6: 1202-1210.

36. SASAJIMA, Yoshiyuki, Kohama, Y., Kojima-Misaizu, M., Kurokawa, N., Hara, Y., Dong, J., et al. Simultaneous retention of thermostability and specific activity in chimeric human alkaline phosphatases. Molecular biotechnology, 2014, 56.10: 953-961.

37. SU, Yang, Zhang, X., Bidlingmaier, S., Behrens, C. R., Lee, N. K., & Liu, B. ALPPL2 is a highly specific and targetable tumor cell surface antigen. bioRxiv, 2020.

38. ACHARYA, Swetha, Kale, J., Rai, P., Anehosur, V., & Hallikeri, K. Serum alkaline phosphatase in oral squamous cell carcinoma and its association with clinicopathological characteristics. South Asian journal of cancer, 2017, 6.3: 125.

39. NGUYEN, Trieu, Chidambara, V. A., Andreasen, S. Z., Golabi, M., Linh, Q. T., Bang, D. D., et al. Point-of-Care Devices for Pathogen Detections: The Three Most Important Factors to Realize towards Commercialization. TrAC Trends in Analytical Chemistry, 2020, 116004.